Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Allergy ; 60(5): 685-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15813816

ABSTRACT

BACKGROUND: Expression of CCR4 ligands, such as thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC), leads to preferential influx of T-helper (Th) 2-type lymphocytes to the lesional skin in atopic dermatitis (AD). Eotaxin, like the CCR3 ligand, is an important contributor of eosinophils recruitment in the course of AD. These chemokines are assumed to play an important role in the pathomechanism of AD. METHODS: In this study, the serum concentration of TARC, MDC, eotaxin and total immunoglobulin E (IgE) in AD patients and healthy people were compared. Correlation between the studied indices and activity of AD was established. Severity of AD was assessed according to the SCORAD score. The study comprised 44 healthy people and 43 patients with AD. The serum concentrations of TARC, MDC, eotaxin and IgE were measured with the use of enzyme-linked immunosorbent assay kits. RESULTS: The serum levels of TARC, MDC, eotaxin and IgE appeared to be significantly higher in patients with AD than in healthy people. A strong positive correlation was revealed between the levels of TARC, MDC, total IgE in serum of patients with AD and SCORAD. In contrast, no significant relationship was found for the serum eotaxin concentration and TARC, MDC, IgE or disease severity. CONCLUSION: Our findings indicate that TARC and MDC are actively involved in the pathogenesis of AD and their expression, opposite to that of eotaxin, is strongly associated with clinical picture of atopic dermatitis.


Subject(s)
Chemokines, CC/blood , Dermatitis, Atopic/physiopathology , Adult , Biomarkers/blood , Case-Control Studies , Chemokine CCL11 , Chemokine CCL17 , Chemokine CCL22 , Dermatitis, Atopic/blood , Female , Humans , Immunoglobulin E/analysis , Male , Osmolar Concentration , Severity of Illness Index
3.
Neurol Neurochir Pol ; 35(6): 1045-54, 2001.
Article in Polish | MEDLINE | ID: mdl-11987701

ABSTRACT

Case records of 200 patients operated on in 1998/99 for herniated lumbar disc in Neurosurgery Dept. showed that 95 patients (47.5%) had been treated previously by 148 alternative medical or non-medical procedures. The authors discuss the problem of non-conventional treatment methods applied for herniated lumbar disc by professionals or non professionals. The procedures are often dangerous.


Subject(s)
Acupuncture Therapy/statistics & numerical data , Intervertebral Disc Displacement/therapy , Lumbar Vertebrae , Musculoskeletal Manipulations/statistics & numerical data , Acupuncture Therapy/psychology , Attitude to Health , Humans , Intervertebral Disc Displacement/psychology , Musculoskeletal Manipulations/psychology , Poland , Surveys and Questionnaires
4.
Pol Merkur Lekarski ; 11(63): 239-43, 2001 Sep.
Article in Polish | MEDLINE | ID: mdl-11761819

ABSTRACT

It was a randomised, double-blind, placebo controlled comparative study of the clinical symptoms and chosen parameters of ventilation of inhaled ambroxol in patients hospitalized with exacerbation of chronic obstructive pulmonary disease (COPD). Eligible patients--30 patients (13 men and 17 women) aged of mean value 70.5 +/- 6.9 years who fulfilled the clinical traits of exacerbation of chronic bronchitis entered the study. 15 patients were treated with inhaled ambroxol and 15 were treated with placebo. Moreover all patients were treated with concomitant medications typical for exacerbation of COPD (systemic steroids, intravenous infusions with euphillin, antibiotics, Berodual nebulizations and oxygen therapy). Spirometry and data related to clinical symptoms were taken at the beginning of the study and after 1 and 3 days and after the end of the treatment. At the end of the treatment period in both groups (inhaled ambroxol therapy vs. placebo) there wasn't found statistically significant difference in the number of cough and dyspnoe attacks. There was found the difference in FEV1 and FEF 50 in both groups, but improvement in patients treated with ambroxol was statistically significantly faster, that can influence the cost of treatment. Moreover there were not found important adverse events in ambroxol group.


Subject(s)
Ambroxol/therapeutic use , Expectorants/therapeutic use , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Administration, Inhalation , Aged , Ambroxol/administration & dosage , Double-Blind Method , Expectorants/administration & dosage , Female , Humans , Male , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...